CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2921-A |

# Specialty Guideline Management Evenity

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Evenity | romosozumab-aqqg |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-Approved Indications1

Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

#### Limitations of Use

Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review: Chart notes or medical record documentation indicating a history of fragility fractures, T-score, and Fracture Risk Assessment Tool (FRAX) fracture probability as applicable to the coverage criteria section.

## Coverage Criteria

### Postmenopausal Osteoporosis1-5,7

Authorization of a total of 12 months may be granted to postmenopausal members with osteoporosis when either of the following criteria is met:

* Member has a history of fragility fractures (e.g., low trauma fracture from force similar to a fall from standing position).
* Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (see Appendix B) and meets any of the following criteria:
  + Member has indicators of very high fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [less than or equal to -3], or increased fall risk)
  + Member has failed prior treatment with or is intolerant to previous injectable osteoporosis therapy (e.g., zoledronic acid [Reclast], teriparatide [Forteo], a denosumab product [Prolia, Jubbonti, Ospomyv, Stoboclo], abaloparatide [Tymlos])
  + Member has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate (see Appendix A)

## Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section and have received less than 12 monthly doses of Evenity.

## Appendix

### Appendix A: Clinical Reasons to Avoid Oral Bisphosphonate Therapy3

* Presence of anatomic or functional esophageal abnormalities that might delay transit of the tablet (e.g., achalasia, stricture, or dysmotility)
* Active upper gastrointestinal problem (e.g., dysphagia, gastritis, duodenitis, erosive esophagitis, ulcers)
* Presence of documented or potential gastrointestinal malabsorption (e.g., gastric bypass procedures, celiac disease, Crohn’s disease, infiltrative disorders)
* Inability to stand or sit upright for at least 30 to 60 minutes
* Inability to take oral bisphosphonate at least 30 to 60 minutes before first food, drink, or medication of the day
* Renal insufficiency (creatinine clearance <35 mL/min)
* History of intolerance to an oral bisphosphonate

### Appendix B: FRAX Fracture Risk Assessment Tool6

* High FRAX fracture 10–year probability: Major osteoporosis-related fracture risk ≥ 20% or hip fracture risk ≥ 3%.
* 10-year probability; calculation tool available at: https://frax.shef.ac.uk/FRAX/
* The estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture (including fractures of the spine [clinical], hip, wrist, or humerus) and 1.2 for hip fracture if glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) per day.

## References

1. Evenity [package insert]. Thousand Oaks, CA: Amgen; April 2024.
2. LeBoff MS, Greenspan SL, Insogna KL, et al. The Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10): 2049-2102.
3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update. Endocr Pract. 2020;26 (Suppl 1):1-46.
4. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1595-1622.
5. Carey, John. What is failure of bisphosphonate therapy for osteoporosis. Cleve Clinic J Med. 2005; 72:1033-1039.
6. FRAX® Fracture Risk Assessment Tool. © Centre for Metabolic Bone Diseases, University of Sheffield, UK. Available at: https://frax.shef.ac.uk/FRAX/. Accessed October 2, 2024.
7. Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med 2017;167(03):ITC17–ITC32.